NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/10/2022
Voltar para busca
Dado oficial do USPTO
KALLYOPE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
04/10/2022
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
26/12/2018
Data de registro
04/10/2022
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/10/2022
Última transação
04/10/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/06/2021
Primeiro uso no comércio
01/06/2021
Código do desenho
4
Tipo de titular
03
Localização do titular
New York, NY
Examinador
YARD, JOHN
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Kallyope, Inc.
Representantes
Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of gastrointestinal diseasesmetabolic diseasesmicrobiome related conditionsneurological diseases and disordersany disease or disorder associated with intestinal permeability; biochemicals for in vitro and in vivo scientific or research use; ; Active chemical ingredients for scientific or research use in the manufacture of pharmaceuticals for the treatment of gastrointestinal diseasesmetabolic diseasesmicrobiome related conditionsneurological diseases and disordersany disease or disorder associated with intestinal permeability
Classe 5
pharmaceutical preparations and substances for the treatment of gastrointestinal diseasesmetabolic diseasesmicrobiome-related conditionsneurological diseases and disordersdiseases and disorders associated with intestinal permeability ; pharmaceutical preparations and substances for treatment of diseases related to the gut-brain axisgut-brain circuits and gut-restricted and gut-targeted molecules
Classe 42
medical and scientific research in the fields of gastrointestinal diseasesmetabolic diseasesmicrobiome-related conditionsneurological diseases and disordersdiseases and disorders associated with intestinal permeability; scientific and medical research and development; biological research and development; bacteriological research and development; pharmaceutical scientific research and development; pharmaceutical new product research and development for others; scientific chemicalbiochemicalbiotechnologicalbiological and bacteriological research and analysis; providing medical and scientific research information in the fields of pharmaceuticalsbiochemistrybiotechnologyclinical trials; medical and scientific research in the fields of diseases of the gut-brain axisgut-brain circuits and gut-restricted and gut-targeted molecules
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
30/08/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/07/2022
EEXT
SOU TEAS EXTENSION RECEIVED
02/06/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/02/2022
GNRT
NON-FINAL ACTION E-MAILED
01/02/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
01/02/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/01/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/01/2022
IUAF
USE AMENDMENT FILED
10/12/2021
EISU
TEAS STATEMENT OF USE RECEIVED
10/12/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/12/2021
EX4G
SOU EXTENSION 4 GRANTED
02/12/2021
EXT4
SOU EXTENSION 4 FILED
02/12/2021
EEXT
SOU TEAS EXTENSION RECEIVED
02/12/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/06/2021
EX3G
SOU EXTENSION 3 GRANTED
01/06/2021
EXT3
SOU EXTENSION 3 FILED
01/06/2021
EEXT
SOU TEAS EXTENSION RECEIVED
01/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/12/2020
EX2G
SOU EXTENSION 2 GRANTED
30/11/2020
EXT2
SOU EXTENSION 2 FILED
30/11/2020
EEXT
SOU TEAS EXTENSION RECEIVED
30/11/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/05/2020
EX1G
SOU EXTENSION 1 GRANTED
21/05/2020
EXT1
SOU EXTENSION 1 FILED
21/05/2020
EEXT
SOU TEAS EXTENSION RECEIVED
21/05/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/12/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2019
PUBO
PUBLISHED FOR OPPOSITION
08/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/09/2019
ALIE
ASSIGNED TO LIE
05/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/08/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/03/2019
GNRT
NON-FINAL ACTION E-MAILED
21/03/2019
CNRT
NON-FINAL ACTION WRITTEN
21/03/2019
DOCK
ASSIGNED TO EXAMINER
18/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/01/2019
NWAP
NEW APPLICATION ENTERED
29/12/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KALLYOPE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.